Patients’ Preferences for Treatment of Hepatitis C

Fraenkel, Liana; Chodkowski, Diane; Lim, Joseph K.; García–Tsao, Guadalupe

doi:10.1177/0272989x09341588

Cited by 36 publications

(33 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with a large amount of literature describing patient preferences for different health care decisions, we found that subjects varied in their preferences for CRC screening tests [33][34][35][36] . What is surprising and interesting in our population is that despite high levels of satisfaction with prior colonoscopy, a significant proportion of patients would choose colon capsule or CT colonography over colonoscopy.…”

Section: Discussionsupporting

confidence: 83%

What Is Most Important to Patients when Deciding about Colorectal Screening?

2010

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 83%

What Is Most Important to Patients when Deciding about Colorectal Screening?

2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fraenkel and colleagues[12] found that HCV-infected patients who perceived higher benefits of treatment were much more willing to accept treatment-related side effects. Similarly, Hauber and colleagues[11] found that increases in the rate of SVR were more than twice as important to patients as avoiding days with flu-like symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…While some evidence of patient preferences regarding HCV treatments exists,[11,12] the available literature focuses on treatment with ribavirin plus interferon or peginterferon. In this paper, we report the results of a choice-format conjoint analysis survey that asked patients to choose among alternative, hypothetical HCV treatments that include characteristics of new DAAs.…”

Section: Introductionmentioning

confidence: 99%

Patients’ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection

Kauf

Mohamed

Hauber

et al. 2012

Patient-Patient-Centered-Outcome-Res

View full text Add to dashboard Cite

BackgroundSome patients with chronic hepatitis C virus (HCV) infection forego treatment due to concerns about treatment efficacy, treatment duration, and side effects.ObjectiveThe purpose of this study was to quantify patient preferences among possible outcomes associated with new, direct-acting antiviral agents (DAAs) for the treatment of HCV infection and determine which treatment features are most important to patients in making treatment decisions.MethodsAdult participants with a self-reported physician diagnosis of HCV infection in five countries completed a web-enabled, choice-format conjoint analysis survey. The survey presented participants with 20 treatment-choice questions. Each treatment-choice question included a pair of hypothetical treatment profiles with varying levels of six attributes: treatment duration; chance of getting rid of the virus completely (i.e. likelihood of a sustained virologic response [SVR]); weeks on an additional, third medicine (i.e. a DAA); risk of a severe rash; risk of severe anemia; and number of times a day the third medicine is taken. Treatment-choice questions were based on a predetermined experimental design with known statistical properties. Random-parameters logit was used to estimate preference weights for all attribute levels and the mean relative importance of each attribute.Results284 participants completed the survey. Likelihood of an SVR was the most important outcome to participants, followed by severe anemia risk, severe rash risk, therapy type (a combination of total weeks of treatment and weeks on the third medicine), and dosing of the third medicine. Controlling for other factors, preferences were similar across all therapy types examined.ConclusionPatients with HCV infection indicate a willingness to accept an increased risk of side effects for sufficient improvement in the likelihood of treatment response.Electronic Supplementary MaterialSupplementary material is available for this article at 10.1007/BF03262498 and is accessible for authorized users.

show abstract

“…'Self-explicated approaches' (SEAs) is a subgroup of stated preference methods that originated in product development and marketing and have become popular due to their ability to determine relative weights for a large number of outcomes with low cognitive burden, small expenses, and relatively undemanding design, analysis and interpretation compared with other methods [20,21]. Research trials applying SEA methods have started to appear in healthcare, and early results indicate that the approaches might be feasible in patients with diverse conditions, including schizophrenia [22][23][24].…”

Section: Introductionmentioning

confidence: 99%